Skip to content
The Policy VaultThe Policy Vault

Gilotrif (afatinib) — Medica

Head and neck cancer

Initial criteria

  • Patient is age ≥ 18 years
  • Patient has non-nasopharyngeal head and neck cancer
  • Patient has disease progression on or after platinum-based chemotherapy

Approval duration

1 year